Close

BIO Applauds Signing of Food and Drug Administration Reauthorization Act (FDARA)

Enactment of FDA User Fee package important victory for patients, medical innovation

Washington, DC (August 18, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding President Trump’s signing of the Food and Drug Administration Reauthorization Act (FDARA) today:

“President Trump’s signature today on this landmark legislation is the culmination of a years-long collaborative process in which patients, industry, FDA, legislators and other stakeholders worked tirelessly to identify ways in which FDA’s human drug review programs can be improved to deliver better health care for every American and enhance the incorporation of the patient voice in drug development and review.  

“BIO is proud to have played a part in these efforts and prouder still of the important advances for patients and medical innovation that this law will help achieve. Whether it be bringing patients’ perspectives more closely to bear in regulatory decision-making, speeding new medicines to market by making the clinical trial process more efficient, or increasing competition from generics and biosimilars, the provisions of this law will make our healthcare system more responsive to the needs of patients.

“We look forward to working with Commissioner Gottlieb to ensure that these critical advancements are most effectively implemented. We thank the leaders from both parties and in both chambers of Congress for their tireless bipartisan efforts in crafting this historic achievement.”

Upcoming BIO Events

BIO Patient and Health Advocacy Summit
October 2-3, 2017
Washington, DC
 

BIO Investor Forum
October 17-18, 2017
San Francisco, CA


###